Table 1

Clinical and immunological characteristic of the SLE participants (n=36)

Characteristicn (%) or median (LQ, UQ)
Female sex34 (94%)
Disease duration (years)10.5 (5, 15)
ANA positive (ever)34 (94.4)
Elevated IgG anti-dsDNA antibody*9 (26)
Low C3 or C4*12 (35)
Anticardiolipin (aCL) antibody-positive*9 (26)
Lupus anticoagulant positive*6 (18)
BILAG total score†1 (0, 2)
SLEDAI-2K2 (0, 2)
SDI0 (0, 1)
9/36 (25%) had a score ≥1
Oral corticosteroids (y/n)12 (33.3)
Average daily corticosteroid dose (mg) (n=12)8.75 (6.25, 11.25)
Current immunosuppressant use15 (41.7)
Current antimalarial use22 (61.1)
Biological medication3 (8.3)
  • *At time of study.

  • †Score calculated as stated in Yee et al. 22

  • ANA, antinuclear antibody; BILAG, British Isles Lupus Assessment Group Index; C3, complement component 3; C4, complement component 4; SDI, The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; IgG ds-DNA, immunoglobulin G double-stranded DNA.